Formulation studies on modified releasing amoxicillin trihydrate microcapsules.
In vitro researches and in vivo animal experiments show that, generally the antibiotic concentration should be above minimum inhibitory concentration for optimal efficiency. There is also direct and indirect evidence from human trials to support this claim. Consequently, a modified-release dosage form of the beta-lactam antibiotics might be therapeutically more efficient than the existing conventional products, which are rapidly absorbed to produce transient peaks in serum drug levels. In our study, Amoxicillin was chosen as the model drug, because it is currently one of the most widely prescribed oral semisynthetic penicillins. By using various types of polymers and different formulations of them, we tried to improve a microparticular system. We succeeded in obtaining optimal production of particulars in the prepared microcapsule form with the solvent evaporation technique. By applying suitable pharmaceutical technological production parameters, the production of the dosage form which releases modified-release form of the model antibiotic is provided. Production processes and availability for the aim is controlled by using the pharmaceutical technological tests, mainly with the methods according to USP XXIV. Consequently compared to the classical Amoxicillin trihydrate dosage forms used in treatment, we managed to form the microcapsule structure containing modified release.